Inhaled mannitol in the treatment of non-cystic fibrosis bronchiectasis in adults

Respirology

Volumn 17, Issue 6, 2012, Pages 927-932

  Gjoerup, Juliana ^a   Hilberg, Ole ^a   Bendstrup, Elisabeth ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

cough; hypertonic saline; mannitol; mucociliary clearance; non cystic fibrosis bronchiectasis

Indexed keywords

MANNITOL;

BRONCHIECTASIS; COUGHING; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FORCED EXPIRATORY FLOW; FORCED VITAL CAPACITY; HUMAN; INHALER; LUNG FUNCTION; MUCOCILIARY CLEARANCE; NONCYSTIC FIBROSIS BRONCHIECTASIS; PARTICLE SIZE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY AIRFLOW; REVIEW; SPUTUM; SPUTUM VISCOSITY; SURFACE TENSION; TREATMENT DURATION; VISCOELASTICITY; WETTABILITY;

ADMINISTRATION, INHALATION; ADULT; BRONCHIECTASIS; HUMANS; LUNG; MANNITOL; MUCOCILIARY CLEARANCE; POWDERS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPUTUM;

EID: 84864424807     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2012.02189.x     Document Type: Review

References (27)

1. Daviskas E, Anderson SD, Brannan SD, et al,. Inhalation of dry-powder mannitol increases mucociliary clearance. Eur. Respir. J. 1997; 10: 2449-54.
2. O'Donell AE,. Bronchiectasis. Chest 2008; 134: 815-23.
3. Stafler P, Carr SB,. Non-cystic fibrosis bronchiectasis: its diagnosis and management. Arch. Dis. Child. Educ. Pract. Ed. 2010; 95: 73-82.
4. Murray MP, Pentland JL, Hill AT,. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur. Respir. J. 2009; 34: 1086-92.
5. Dentice R,. Airway clearance physiotherapy improves quality of life in people with bronchiectasis. Aust. J. Physiother. 2009; 55: 285.
6. Fuchs HJH, Borowitz DS, Christiansen DH,. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and in pulmonary function in patients with cystic fibrosis. The Pulmozime Study Group. N. Engl. J. Med. 1994; 331: 637-42.
7. O'Donnell AE, Barker AF, Ilowite JS,. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase. Chest 1998; 113: 1329-34.
8. Elborn JS, Jonhston B, Allen F,. Inhaled steroids in patients with bronchiectasis. Respir. Med. 1992; 86: 121-4.
9. Tsang KW, Tan KC, Ho PL,. Inhaled fluticasone in bronchiectasis: a 12 months study. Thorax 2005; 60: 239-43.
10. Sheikh A, Nolan D, Greenstone M,. Long-acting beta-2 agonists for bronchiectasis. Cochrane Database Syst. Rev. 2001; (4): CD002155.
11. Daviskas E, Robinson M, Anderson SD,. Osmotic stimuli increase clearance of mucus in patients with mucociliary dysfunction. J. Aerosol Med. 2002; 15: 331-41.
12. Daviskas E, Anderson SD,. Hyperosmolar agents and clearance of mucus in the diseased airway. J. Aerosol Med. 2006; 19: 101-9.
13. Bilton D, Robinson P, Cooper P, et al,.; CF301 Study Investigators. Inhaled dry-powder mannitol in cystic fibrosis: an efficacy and safety study. Eur. Respir. J. 2011; 38: 1071-80.
14. Daviskas E, Anderson SD, Eberl S, et al,. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 1999; 159: 1843-8.
15. Daviskas E, Anderson SD, Eberl S, et al,. The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest 2001; 119: 414-21.
16. Daviskas E, Anderson SD, Eberl S, et al,. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur. Respir. J. 2008; 31: 765-72.
17. Daviskas E, Anderson SD, Eberl S, et al,. Beneficial effect of inhaled mannitol and cough in asthmatics with mucociliary dysfunction. Respir. Med. 2010; 104: 1645-53.
18. Daviskas E, Anderson SD, Young IH,. Effect of mannitol and repetitive coughing on the sputum properties in bronchiectasis. Respir. Med. 2010; 104: 371-7.
19. Daviskas E, Anderson SD, Gomes K, et al,. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 2005; 10: 46-56.
20. Goldman MD, Daviskas E, Turton JA, et al,. Inhaled mannitol improves lung function assessed by forced oscillation in a placebo controlled trial in patients with bronchiectasis. Eur. Respir. J. 2004; 24: 470s-471s.
21. Briffa PJ, Anderson SD, Burton DL, et al,. Sodium cromoglycate and eformoterol attenuate sensitivity and reactivity to inhaled mannitol in subjects with bronchiectasis. Respirology 2011; 16: 161-6.
22. Loebinger MR, Wells AU, Hansell DM, et al,. Mortality in bronchiectasis: a long term study assessing the factors influencing survival. Eur. Respir. J. 2009; 34: 843-9.
23. Murray MP, Turnbull K, MacQuarrie S, et al,. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur. Respir. J. 2009; 33: 312-17.
24. Jones PW, Quirk FH, Baveystock CM, et al,. A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am. Rev. Respir. Dis. 1992; 145: 1321-7.
25. Wilson CB, Jones PW, O'Leary CJ, et al,. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am. J. Respir. Crit. Care Med. 1997; 156: 536-41.
26. Ferrer M, Villasante C, Alonso J,. Interpretation of quality of life scores from the St. George's Respiratory Questionnaire. Eur. Respir. J. 2002; 19: 405-13.
27. Murray MP, Turnbull K, MacQuarrie S, et al,. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur. Respir. J. 2009; 34: 125-31.